DANOCRINE
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Jun 1976
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 5h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DANOCRINE is a legacy oral small-molecule capsule approved in 1976 with an unknown mechanism of action and indication profile. As a product approaching loss of exclusivity, it represents a mature market position within Sanofi's portfolio. The specific therapeutic uses and patient population cannot be fully characterized due to missing indication data.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30/100), suggesting a contracting team focused on managed decline and generic transition preparation.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
DANOCRINE offers limited career growth opportunity as a legacy product in LOE decline. Roles available are primarily defensive and focused on maximizing remaining exclusivity period and managing generic transition.
Brand ManagerField Sales
Worked on DANOCRINE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.